Web Exclusive
Glenmark, Alembic, Cipla: Pharma stocks on a booster dose this December

Nifty Pharma Likely target: 14,400 Upside potential: 5% The index is struggling to sustain above the 200-days moving average (DMA) placed at 13712 levels, according to the daily chart. However, the 50-weekly moving average (WMA) which is located at 13,578 provides a crucial support at the current juncture. As long as the index conquers and hold above the 200-DMA keeping the support at 13,578 levels, it may see a sharp rally towards 14,400 levels over the next few sessions, charts suggest. CLICK HERE FOR THE CHART Alembic Pharmaceuticals Ltd (APLLTD) Likely target: Rs 950 Upside poten.....
Nifty Pharma

Likely target: 14,400

Upside potential: 5%

The index is struggling to sustain above the 200-days moving average (DMA) placed at 13712 levels, according to the daily chart. However, the 50-weekly moving average (WMA) which is located at 13,578 provides a crucial support at the current juncture. As long as the index conquers and hold above the 200-DMA keeping the support at 13,578 levels, it may see a sharp rally towards 14,400 levels over the next few sessions, charts suggest. CLICK HERE FOR THE CHART

Alembic Pharmaceuticals Ltd (APLLTD)

Likely target: Rs 950

Upside potential: 15%

Though there is a major breakdown below the support of Rs 850 levels, but Alembic Pharma have managed to stay above Rs 700, which is the 200-WMA as per the weekly chart. The continued effort to overcome the barrier of Rs 850 shows the positive underlying strength and a possible upside in the sessions ahead. Thus, as long as the support of Rs 700 is held, the momentum may see a rally in the direction of Rs 950. CLICK HERE FOR THE CHART

Cipla Ltd (CIPLA)

Likely target: Rs 1,100

Upside potential: 13%

After almost 30 sessions, the Moving Average Convergence Divergence (MACD) has crossed the zero line upward with a positive crossover. This indicates robust underlying strength. Though the stock is trading 4 per cent lower from its all-time high, the there is underlying strength that can take this counter towards Rs 1,100 levels as long as the support of Rs 900 is held firmly. CLICK HERE FOR THE CHART

Glenmark Pharmaceuticals (GLENMARK)

Likely target: Rs 600

Upside potential: 15%

Glenmark Pharma has seen selling pressure around Rs 670 levels and this has led to a decline of over 25 per cent recently. While the negative pressure is strong, the counter has managed to stay above the 200-WMA support placed at Rs 487 levels, as per the weekly chart. Going ahead, Glenmark may make an attempt to cross the recent hurdles and move towards Rs 600, charts suggest. CLICK HERE FOR THE CHART

 

Torrent Pharmaceuticals Ltd (TORNTPHARM)

Likely target: Rs 3,300

Upside potential: 11%

The “Higher High, Higher Low” formation is intact for now and the stock looks positive on the charts. The bullish sentiment may see a jump towards Rs 3,300 levels, according to the weekly chart. Support stays at Rs 2,800 mark. CLICK HERE FOR THE CHART


Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel
Read More on

PHARMACEUTICAL FIRMS

STOCKS TECHNICAL ANALYSIS

TRADING STRATEGIES

PHARMA STOCKS

CIPLA

ALEMBIC PHARMACEUTICALS

GLENMARK PHARMACEUTICALS

NIFTY PHARMA

MARKETS

NEWS


Most Read

Markets

Companies

Opinion

Latest News

Todays Paper

News you can use